Bristol-Myers' Big Bet on ImClone
News posting on July 31, 2008 | Related to Adnexus Therapeutics
ImClone’s pipeline of cancer-fighting compounds could fill a big gap in Bristol’s portfolio after key drugs go off patent, say analysts
Source: BusinessWeek
